As pharmaceutical innovation continues to thrive, novel categories of ultra-high cost drugs called gene and cell therapies, which may near or exceed a million dollars per single treatment course, are entering the market. By 2025, the FDA predicts they will be reviewing and approving 10-20 gene and cell therapies per year.

As the gene and cell therapy market continues to develop, targeted solutions to address cost of care and support clinical outcomes are beginning to emerge. Join Mercer experts as we explore what actions plan sponsors should consider in order to build a long term comprehensive management strategy for these therapies.

HR leaders and anyone who participates in employee health & benefits programs and strategies.